Long remissions in hairy cell leukemia with purine analogs

Both pentostatin and cladribine have efficacy in hairy cell leukemia (HCL), but it is not known which agent achieves better results.

[1]  S. Verstovsek,et al.  Phase II study of cladribine (2CDA) followed by rituximab for eradication of minimal residual disease (MRD) in hairy cell leukemia (HCL) , 2005 .

[2]  S. Galimberti,et al.  Rituximab as treatment for minimal residual disease in hairy cell leukaemia , 2004, European journal of haematology.

[3]  T. Haferlach,et al.  An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine , 2004, Leukemia.

[4]  S. Pileri,et al.  Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. , 2004, Haematologica.

[5]  H. Kantarjian,et al.  Rituximab in relapsed or refractory hairy cell leukemia. , 2003, Blood.

[6]  A. Saven,et al.  Cladribine in the treatment of hairy-cell leukaemia. , 2003, Best practice & research. Clinical haematology.

[7]  J. Koziol,et al.  Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Coiffier,et al.  Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients , 2003, Leukemia.

[9]  H. Hagberg,et al.  Rituximab, a chimaeric anti‐CD20 monoclonal antibody, in the treatment of hairy cell leukaemia , 2001, British journal of haematology.

[10]  W. Wilson,et al.  Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. , 2001, The New England journal of medicine.

[11]  R. Foà,et al.  Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. , 2001, Haematologica.

[12]  M. Grever,et al.  Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. , 2000, Blood.

[13]  E. Eisenhauer,et al.  Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. , 2000, Seminars in oncology.

[14]  E. Montserrat,et al.  Deoxycoformycin in the treatment of patients with hairy cell leukemia , 2000, Cancer.

[15]  D. Catovsky,et al.  Long‐term follow‐up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine , 1999, British journal of haematology.

[16]  M. Grever,et al.  Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  G. Salles,et al.  Long term outcome of patients with hairy cell leukemia treated with pentostatin , 1999, Cancer.

[18]  J. Koziol,et al.  Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. , 1998, Blood.

[19]  J. Connors,et al.  Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  D. Catovsky,et al.  The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long‐term follow‐up study , 1997, British journal of haematology.

[21]  M. Hoffman,et al.  Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Rademaker,et al.  Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. , 1996, Blood.

[23]  D. Catovsky,et al.  2‐Chlorodeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy , 1996, British journal of haematology.

[24]  L. Peterson,et al.  Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. , 1996, Blood.

[25]  M. Grever,et al.  Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Grever,et al.  Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin. , 1994, Blood.

[27]  A. Saven,et al.  Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. , 1994, Blood.

[28]  S. Horning,et al.  Pentostatin treatment for hairy cell leukemia patients who failed initial therapy with recombinant alpha-interferon: a report of CALGB study 8515. , 1994, Leukemia.

[29]  A. Delannoy,et al.  A single course of 2-chloro-deoxyadenosine does not eradicate leukemic cells in hairy cell leukemia patients in complete remission. , 1994, Leukemia.

[30]  M. Colleoni,et al.  Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma. , 1994, Leukemia & lymphoma.

[31]  H. Gerhartz,et al.  Prognosis of high dose chemotherapy/autologous bone marrow transplantation candidates not receiving this treatment after failure of primary therapy of Hodgkin's disease. , 1994, Leukemia & lymphoma.

[32]  D. Catovsky,et al.  Incidence and significance of abdominal lymphadenopathy in hairy cell leukaemia. , 1994, Leukemia & lymphoma.

[33]  K. Rai.  Comparison of pentostatin and alpha interferon in splenectomized patients with active hairy cell leukemia: an intergroup study. Cancer and Leukemia Group B and South-West Oncology Group. , 1994, Leukemia and Lymphoma.

[34]  A. Saven,et al.  The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. , 1994, Leukemia & lymphoma.

[35]  D. Catovsky,et al.  Long term results with 2'deoxycoformycin in hairy cell leukemia. , 1994, Leukemia & lymphoma.

[36]  L. Peterson,et al.  Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. , 1993, Blood.

[37]  A. Saven,et al.  Complete Remissions in Hairy Cell Leukemia with 2-Chlorodeoxyadenosine after Failure with 2-Deoxycoformycin , 1993, Annals of Internal Medicine.

[38]  A. Ho,et al.  Long‐term follow‐up of patients with hairy cell leukaemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration , 1993, British journal of haematology.

[39]  E. Estey,et al.  Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). , 1992, Blood.

[40]  G. Juliusson,et al.  Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections. , 1992, Blood.

[41]  M. O’connell,et al.  Pentostatin induces durable remissions in hairy cell leukemia. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  D. Carson,et al.  Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. , 1990, The New England journal of medicine.

[43]  F. Mandelli,et al.  Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. The European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Grever,et al.  Pentostatin in the treatment of advanced hairy cell leukemia. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  D. Catovsky,et al.  Guidelines for the treatment of hairy cell leukemia. , 1987, Leukemia.

[46]  Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia. , 1987, Leukemia.

[47]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[48]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[49]  D.,et al.  Regression Models and Life-Tables , 2022 .